Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...

Dr Marina Garassino speaks to ecancer at ESMO 2019 in Barcelona commenting on the FLAURA trial.

The trial was looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.

Dr Garassino comments because smaller facilities may not have the capability to do full sequencing, having multiple treatment options is still important in order to personalise treatment for these patients where possible.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

positi...